Over 150 Total Lots Up For Auction at One Location - CA 05/31

Oligonucleotide-Based Therapeutics to Be Discussed by Industry Experts at DIA Conference

by Joan Trombetti, Writer | August 19, 2008
Keynote Speaker
Craig C. Mello, PhD,
UMass Medical School
and 2006 Nobel Laureate
HORSHAM, PA - The Drug Information Association (DIA), in collaboration with the FDA, Oligonucleotide Therapeutics Society, Health Canada, and the American Association of Pharmaceutical Scientists, will host the 2nd Conference on Oligonucleotide-based Therapeutics (September 22 & 24 Falls Church, VA).

"Attendees can share product development and regulatory information in the areas of nonclinical, chemistry, manufacturing and control (CMC),and clinical development of Oligonucleotide- based therapeutic drugs with industry experts and international regulators," says Program Co-chair David H. Schubert, Vice President of Regulatory Affairs, Logical Therapeutics, Inc.

Keynote speakers will include Craig C. Mello, PhD, University of Mass Medical School and 2006 Nobel Laureate, and Alan B. Sachs, MD, PhD, Merck Research Laboratories. The final day will feature a panel discussion with representatives from the EMEA, FDA, Health Canada and PMDA.

About the Drug Information Association (DIA)
DIA serves more than 30,000 professionals in the biotechnology, pharmaceutical and regulatory industries worldwide. Through its domestic and international meetings, training courses, workshops and webinars, DIA provides a neutral global forum for the exchange of information critical to the advancement of the drug discovery and lifecycle management processes. Headquartered in Horsham, PA, USA, and with offices in Basel, Switzerland, Tokyo, Japan, and Mumbai, India, the Association is led by its volunteer-based Board of Directors and executive management team. For more information, visit www.diahome.org.